India Court Suspends Sun-Ranbaxy Merger For Insider-Trading Probe
This article was originally published in PharmAsia News
Executive Summary
A state high court in India ordered regulators and all parties involved in the $4 billion Sun Pharmaceutical Industries purchase of Ranbaxy Laboratories from Daiichi Sankyo while it reviews an insider-trading charge.